Is Autolus Therapeutics plc (AUTL) a Buy, Sell, or Hold?
Autolus Therapeutics plc
NASDAQ:AUTL
$1.51 USD
$0.06 (4.14%)
- Volume
- 1.44M
- Average Volume
- 1.37M
- Market Capitalization
- $401.88M
- P/E Ratio
- -1.39
- Dividend Yield
- 0.00%
- Price Target
- $8.00
- Year High
- $2.70
- Year Low
- $1.18
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.80
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Christian Martin Itin |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AUTL |
| CUSIP | 05280R100 |
| CIK | 0001730463 |
| Web | https://www.autolus.com |
| Phone | 44 20 3829 6230 |
| Currency | USD |
| Employees | 752 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.73 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.80 |
| Quick Ratio | 5.28 |
| Cash Ratio | 2.06 |
Sales & Book Value
| Annual Sales | $75.56M |
| Price / Sales | 4.34 |
| Cash Flow | -1.10 |
| Price / Cash Flow | -1.38 |
| Price / Book | 3.69 |
Price Target and Rating
| Average Stock Price Forecast | $8.00 |
| High Stock Price Forecast | $11.00 |
| Low Stock Price Forecast | $7.60 |
| Forecast Upside/Downside | -81.13% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.08 |
| Trailing P/E Ratio | -1.39 |
| PEG Ratio | 0.06 |
| P/E Growth | 0.06 |
| Net Income | $-288.2M |
| Net Margin | -311.95% |
| Pretax Margin | -311.29% |
| Return on Equity | -128.53% |
| Return on Assets | -54.80% |
Financials Score
| AltmanZ Score | -3.96 |
| Piotroski Score | 4.00 |
| Working Capital | 305.24M |
| Total Assets | 527.06M |
| Ebit | -243.8M |
| Market Cap | 393.89M |
| Total Liabilities | 418.24M |
Poll Results
About Autolus Therapeutics plc (NASDAQ:AUTL) Stock
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in ... preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
2026-07-08 09:35:14
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 16:05:00
LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 13 employees pursuant to the Company's 2025 Inducement Plan.
Autolus Therapeutics to Participate in Upcoming Investor Conference
2026-06-25 07:00:00
LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in the H.C.
Autolus Therapeutics Receives Prix Galien UK Award
2026-06-12 04:00:00
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product.
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-06-10 10:56:08
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
2026-06-01 10:56:20
Autolus Therapeutics PLC Sponsored ADR (AUTL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AUTL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Autolus Therapeutics to Participate in Upcoming Investor Conferences
2026-05-27 07:00:00
LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.
2026-05-21 17:10:00
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.
Frequently Asked Questions
-
What is the current Autolus Therapeutics plc (AUTL) stock price?
-
Autolus Therapeutics plc(NASDAQ:AUTL) stock price is $1.51 in the last trading session. During the trading session, AUTL stock reached the peak price of $2.7 while $1.175 was the lowest point it dropped to. The percentage change in AUTL stock occurred in the recent session was 4.14% while the dollar amount for the price change in AUTL stock was $0.06.
-
AUTL's industry and sector of operation?
-
The NASDAQ listed AUTL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AUTL?
-
Christian Martin Itin | Chief Executive Officer & Director
Chris Williams | Senior VP & Chief Business Development Officer
Martin Pule MBBS | Founder, Senior Vice President & Chief Scientific Officer
Matthias Will | Senior Vice President & Chief Development Officer
Alexander Swan | Senior Vice President & Chief Human Resources Officer -
How many employees does AUTL have?
-
Number of AUTL employees currently stands at 752. AUTL operates from The MediaWorks, London, GL W12 7FP, GB.
-
Link for AUTL official website?
-
Official Website of AUTL is: https://www.autolus.com
-
How do I contact AUTL?
-
AUTL could be contacted at phone #44 20 3829 6230 and can also be accessed through its website. AUTL operates from The MediaWorks, London, GL W12 7FP, GB.
-
How many shares of AUTL are traded daily?
-
The average number of AUTL shares traded daily for last 3 months was 1.37M.
-
What is the market cap of AUTL currently?
-
The market value of AUTL currently stands at $401.88M with its latest stock price at $1.51